Xspray Pharma AB (publ) (STO:XSPRAY)
Sweden · Delayed Price · Currency is SEK 10.10
+0.17 (1.71%)
Sep 2, 2026, 5:29 PM CET
Xspray Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other Revenue | 2.47 | 2.47 | - | - | - | - |
| 2.47 | 2.47 | - | - | - | - | |
Revenue Growth | - | - | - | - | - | - |
Gross Profit | 2.47 | 2.47 | - | - | - | - |
Selling, General & Admin | 143.71 | 151.1 | 203.88 | 169.57 | 109.6 | 58.38 |
Research & Development | 6.18 | 10.75 | 79.36 | 40.26 | 22.22 | 38.57 |
Other Operating Expenses | -0.25 | -0.25 | - | -29.06 | -0.44 | - |
Operating Expenses | 149.64 | 161.6 | 283.24 | 180.77 | 131.38 | 96.95 |
Operating Income | -147.17 | -159.13 | -283.24 | -180.77 | -131.38 | -96.95 |
Interest Expense | -22.8 | -16.85 | -1.93 | -0.68 | -0.01 | -0 |
Interest & Investment Income | 2.02 | 2.22 | 3.3 | 2.73 | 1.42 | 1.26 |
Currency Exchange Gain (Loss) | 8.44 | 2.22 | -3.79 | -0.96 | -1.69 | -1 |
Other Non Operating Income (Expenses) | -0 | -0 | -0 | - | - | -0 |
EBT Excluding Unusual Items | -159.52 | -171.55 | -285.66 | -179.68 | -131.67 | -96.7 |
Gain (Loss) on Sale of Assets | - | - | -0.02 | -0.01 | - | - |
Pretax Income | -159.52 | -171.55 | -285.67 | -179.68 | -131.67 | -96.7 |
Income Tax Expense | -0.08 | -0.1 | -0.15 | -0.02 | - | - |
Net Income | -159.44 | -171.44 | -285.52 | -179.67 | -131.67 | -96.7 |
Net Income to Common | -159.44 | -171.44 | -285.52 | -179.67 | -131.67 | -96.7 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 42 | 38 | 33 | 27 | 21 | 19 |
Shares Outstanding (Diluted) | 42 | 38 | 33 | 27 | 21 | 19 |
Shares Change | 17.03% | 16.04% | 24.61% | 26.21% | 9.53% | 11.77% |
EPS (Basic) | -3.82 | -4.46 | -8.62 | -6.76 | -6.25 | -5.03 |
EPS (Diluted) | -3.82 | -4.46 | -8.62 | -6.76 | -6.25 | -5.03 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -150.35 | -193.16 | -226.75 | -205.97 | -134.65 | -52.92 |
Free Cash Flow Per Share | -3.60 | -5.02 | -6.84 | -7.75 | -6.39 | -2.75 |
Gross Margin | 100.00% | 100.00% | - | - | - | - |
Operating Margin | -5968.01% | -6453.12% | - | - | - | - |
Profit Margin | -6465.49% | -6952.27% | - | - | - | - |
Free Cash Flow Margin | -6096.71% | -7833.05% | - | - | - | - |
EBITDA | -144.96 | -156.54 | -277.76 | -174.27 | -123.04 | -89.07 |
D&A For EBITDA | 2.21 | 2.59 | 5.48 | 6.49 | 8.34 | 7.89 |
EBIT | -147.17 | -159.13 | -283.24 | -180.77 | -131.38 | -96.95 |